Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
(NQ:
QNTM
)
2.860
+0.020 (+0.70%)
Streaming Delayed Price
Updated: 11:48 AM EDT, Jul 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
22,100
Open
2.860
Bid (Size)
2.750 (100)
Ask (Size)
2.900 (100)
Prev. Close
2.840
Today's Range
2.780 - 2.895
52wk Range
2.070 - 31.91
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
July 21, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal
July 21, 2026
Via
Investor Brand Network
Performance
YTD
-59.2%
-59.2%
1 Month
-25.7%
-25.7%
3 Month
-10.9%
-10.9%
6 Month
-54.6%
-54.6%
1 Year
-87.4%
-87.4%
More News
Read More
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
July 14, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
July 14, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
July 09, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast
July 01, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study
June 26, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis
June 26, 2026
Via
Investor Brand Network
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
June 26, 2026
From
NetworkNewsWire
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
June 25, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
June 24, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
June 23, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
June 23, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
From
BioMedWire
Via
GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
From
BioMedWire
Via
GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
June 08, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
June 03, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services
June 02, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
June 02, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
June 02, 2026
Via
Investor Brand Network
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
June 02, 2026
From
Quantum BioPharma
Via
GlobeNewswire
Frequently Asked Questions
Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 2.860
When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 07/24/26 11:48 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
